Bioverativ beefs up its pipeline of rare blood disease drugs with $825M True North buyout
Biogen spin-off Bioverativ isn’t just passively managing the portfolio of hemophilia drugs it’s been given. The biotech just struck a deal to buy South San Francisco-based True North Therapeutics for $400 million in cash plus another $425 million in milestones.
The prize in this deal is TNT009, an experimental drug for cold agglutinin disease, or CAD, a rare and chronic hemolytic condition that often leads to severe anemia. True North has been prepping plans for a pivotal program for the therapy after winning the FDA’s breakthrough therapy designation to help speed it along the regulatory pathway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
